Dr Pascal GEORGE
SCT & SCIENTIFIC EXPERT & ADVISER IN DRUG DESIGN AND DEVELOPMENT, Longvilliers, France
Steroid Sulfatase Inhibition: from Concept to Clinical and Beyond (PL07)
Prof. Barry POTTER
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Barry Potter studied Chemistry at Oxford, completing a DPhil on enzyme-catalyzed phosphoryl transfer stereochemistry with a DSc in 1993. After postdocs in Oxford and at the Max-Planck-Institute in Göttingen, he was lecturer in Biological Chemistry at Leicester, winning a Lister Institute Fellowship, then moved to the chair of Medicinal Chemistry at Bath. Research interests are in mechanistic enzymology, signal transduction chemistry and anticancer drug discovery. He has published over 550 papers, is inventor of 45 granted US patents and has brought academically-discovered drugs to multiple human clinical trials with clinical benefit. In 2015 he became Professor of Medicinal & Biological Chemistry at Oxford. He has won four interdisciplinary RSC medals, the GSK International Achievement Award, a European Life Science Award, held the 2015 RSC Medicinal Chemistry Endowed Lectureship and won the 2018 Tu Youyou Award for his work in Medicinal and Natural Product Chemistry. He was elected to the Academy of Medical Sciences and Academia Europaea.
Recent Advances In Breast Cancer Treatment: Discovery of Amcenestrant (SAR439859), An Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) to Treat ER+ Breast Cancers (PL08)
Dr Youssef EL AHMAD
SANOFI, Vitry Sur Seine, France
Youssef El Ahmad is a Group leader of Medicinal Chemistry at Sanofi.
After a MsC degree from Lebanese University and a PhD in Pharmaceutical Sciences from the Faculty of Pharmacy of Paris XI University, he joined the Medicinal Chemistry department at Sanofi 30 years ago.
During his career, he supports and leads projects in CNS, anti-infective and oncology fields and contributes to the development of several clinical candidates especially for cancer treatment.
In this congress, he presents the “Recent Advances in Breast Cancer Treatment: Discovery of SAR439859, a Selective Estrogen Receptor Degrader for the Treatment of Estrogen-Receptor-Positive Breast Cancer”.
Networking & Exhibition break
Dr Olivier MIRGUET
EVOTEC, Toulouse, France
Daridorexant - a Dual Orexin Receptor Antagonist (PL09)
Dr Christoph BOSS
IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland
Christoph Boss is Vice President, Head of Drug Discovery Chemistry
PhD, synthetic organic chemistry at the University of Bern, Switzerland followed by post-doctoral training at The Scripps Research Institute (TSRI) in LaJolla, California, USA.
From 1999 until 2012, various positions of increasing responsibility in Actelion's drug discovery chemistry department contributing to the identification of several lead compounds including macitentan for PAH and ACT-541468 for insomnia. Senior Group Leader Chemistry Technologies 2012-2017. Joined Idorsia when the company was established in June 2017 as a Senior Group Leader in Drug Discovery Chemistry. Head of Drug Discovery Chemistry at Idorsia since July 2019.
Anti-Virulence Agent to Treat S. Aureus Infections (IL03)
Dr Alessia MICHELOTTI
BIOVERSYS AG, Lille, France
Alessia Michelotti received her M.Sc. at the University of Turin where she studied carborane-based theranostic agents for Boron Neutron Capture Therapy applications with Prof. Annamaria Deagostino. She obtained her PhD in Chemistry in 2019 at Paris-Saclay University in collaboration with CortecNet, under the supervision of Dr. Charlotte Martineau-Corcos and Dr. Maxime Roche where she developed metal-catalyzed C-H deuteration and 13C labelling of endogenous bioactive molecules for DNP-NMR/MRI studies. She then joined BioVersys in Lille in 2019 as a junior researcher in medicinal chemistry, involved in the development of first-in-class stand-alone anti-virulence small molecule drugs for the treatment of MRSA (Methicillin-resistant Staphylococcus Aureus) infections.
End of morning session